Prot # GS-US-218-1227: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection

Project: Research project

Project Details

StatusFinished
Effective start/end date11/13/1411/13/17

Funding

  • PPD Development (GS-US-218-1227)
  • Gilead Sciences, Inc. (GS-US-218-1227)